IDEXX Laboratories, Inc. $IDXX Shares Sold by Jensen Investment Management Inc.

Jensen Investment Management Inc. reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 57.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,430 shares of the company’s stock after selling 5,980 shares during the period. Jensen Investment Management Inc.’s holdings in IDEXX Laboratories were worth $2,830,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of IDXX. Geode Capital Management LLC raised its holdings in IDEXX Laboratories by 2.3% in the second quarter. Geode Capital Management LLC now owns 2,464,290 shares of the company’s stock valued at $1,317,875,000 after acquiring an additional 54,402 shares in the last quarter. Bank of New York Mellon Corp lifted its position in IDEXX Laboratories by 41.7% in the third quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock valued at $1,313,992,000 after acquiring an additional 605,290 shares during the last quarter. Principal Financial Group Inc. grew its stake in IDEXX Laboratories by 16.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock worth $840,638,000 after buying an additional 187,967 shares during the last quarter. William Blair Investment Management LLC grew its position in shares of IDEXX Laboratories by 7.5% during the second quarter. William Blair Investment Management LLC now owns 685,088 shares of the company’s stock worth $367,440,000 after acquiring an additional 47,977 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of IDEXX Laboratories by 1.8% in the 2nd quarter. Legal & General Group Plc now owns 648,626 shares of the company’s stock valued at $347,884,000 after acquiring an additional 11,768 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on the company. Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Jefferies Financial Group reiterated a “buy” rating and issued a $830.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. UBS Group decreased their target price on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 3rd. BTIG Research lowered their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Finally, JPMorgan Chase & Co. lifted their price objective on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $783.33.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $646.53 on Wednesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The business’s 50-day simple moving average is $690.23 and its 200-day simple moving average is $667.06. The firm has a market capitalization of $51.63 billion, a P/E ratio of 49.47, a P/E/G ratio of 3.89 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the business earned $2.53 earnings per share. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.